|
WO2006086748A2
|
|
Genetic markers in the csf2rb gene associated with an adverse hematological response to drugs
|
|
BRPI0510691A
|
|
haplotype markers and methods of using them to determine response to treatment
|
|
WO2005072152A2
|
|
Apoc1 genetic markers associated with age of onset of alzheimer's disease
|
|
CA2555367A1
|
|
Apoe genetic markers associated with age of onset of alzheimer's disease
|
|
US2006154265A1
|
|
LDLR genetic markers associated with age of onset of Alzheimer's Disease
|
|
US2005255495A1
|
|
SLC5A7 genetic markers associated with age of onset of Alzheimer's disease
|
|
CA2547033A1
|
|
Ntrk1 genetic markers associated with progression of alzheimer's disease
|
|
US2005250121A1
|
|
NTRK2 genetic markers associated with progression of Alzheimer's disease
|
|
US2005250122A1
|
|
APOA4 genetic markers associated with progression of Alzheimer's disease
|
|
US2005255492A1
|
|
CHRNA9 genetic markers associated with progression of Alzheimer's disease
|
|
US2005250118A1
|
|
EPHX2 Genetic markers associated with galantamine
|
|
US2005260613A1
|
|
LRPAP1 genetic markers associated with galantamine
|
|
US2005255488A1
|
|
NTRK1 genetic markers associated with age of onset of Alzheimer's Disease
|
|
WO2005021796A2
|
|
Chrna2 genetic markers associated with galantamine response
|
|
WO2005048012A2
|
|
Methods for haplotype assignment
|
|
AU2003284111A1
|
|
Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol
|
|
AU2003280285A1
|
|
Gucy1b2 genetic markers for ldl cholesterol response to statin therapy
|
|
WO03091698A2
|
|
Cetp genetic markers for statin-specific changes in hdl cholesterol
|
|
WO03014319A2
|
|
Polymorphisms associated with multiple sclerosis
|
|
EP1339879A2
|
|
Method of identifying a polymorphism in cyp2d6
|
